Valuation: Actuate Therapeutics, Inc.

Market Cap 28.23M 24.82M 23.1M 21.22M 39.84M 2.71B 40.37M 275M 107M 1.34B 106M 104M 4.62B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 28.23M 24.82M 23.1M 21.22M 39.84M 2.71B 40.37M 275M 107M 1.34B 106M 104M 4.62B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
85.17%
Yield 2026 *
-
Yield 2027 * -
1 day-2.54%
1 week-17.86%
Current month-24.84%
1 month-27.22%
3 months-59.65%
6 months-78.90%
Current year-81.21%
1 week 1.11
Extreme 1.11
1.5
1 month 1.11
Extreme 1.11
1.95
Current year 1.11
Extreme 1.11
7.05
1 year 1.11
Extreme 1.11
9.22
3 years 1.11
Extreme 1.11
11.99
5 years 1.11
Extreme 1.11
11.99
10 years 1.11
Extreme 1.11
11.99
Manager TitleAgeSince
Chief Executive Officer 64 01/03/2015
Director of Finance/CFO 58 01/02/2024
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 64 01/04/2015
Chairman 46 01/04/2015
Director/Board Member 66 01/03/2021
Date Insider Type Main position Quantity % Market Cap.
21/5/26 Free

Director

15,000 0.0633%
21/5/26 Free

Director

15,000 0.0633%
21/5/26 Free

Director

15,000 0.0633%
Change 5-day change 1-year change 3-year change Capi.($)
-2.54%-17.86%-83.24% - 28.23M
-1.82%+5.03%+56.71%+66.69% 57.28B
-0.27%+5.74%+40.26%+80.17% 54.99B
-2.05%-2.14%+2.93%+413.38% 23.18B
+1.97%-1.16%-19.24%-13.25% 22.59B
-1.13%+4.54%+22.73%-8.06% 20.46B
+1.57%+2.09%+28.01%-27.56% 17.56B
-0.10%+5.57%+38.63%+565.16% 15.67B
+5.29%0.00%+185.09%+332.66% 14.46B
+0.79%+0.50%+25.73%+184.74% 13.92B
Average +0.25%-0.35%+29.76%+177.10% 24.01B
Weighted average by Cap. -0.06%+1.93%+40.35%+137.85%

Financials

2026 *2027 *
Net sales - -
Net income - -
Net Debt - -
Logo Actuate Therapeutics, Inc.
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). The Company is developing elraglusib, a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3b, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, which lead to tumor cell survival, growth, migration, and invasion. Its candidate products are Elraglusib Injection and Elraglusib Oral Tablet. Elraglusib is the lead drug in the portfolio and is being evaluated in a randomized Phase II trial in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Elraglusib is designed to act as a mediator of antitumor immunity through the inhibition of NF-kB and regulates multiple immune checkpoints and immune cell function.
Employees
12
Date Price Change Volume
28/07/26 USD 1.150 -2.54% 224,527
24/07/26 USD 1.180 -6.35% 93,561
23/07/26 USD 1.260 -0.40% 118,313
22/07/26 USD 1.265 -6.30% 128,224
21/07/26 USD 1.350 -3.57% 114,704
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.180USD
Average target price
9.978USD
Spread / Average Target
+745.55%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ACTU Stock